Research Information System
in: Tumor Microenvironmet-Siganling Pathways (B), Alexander Birbrair, Editor, Springer, London/Berlin , Zug, pp.23-33, 2021
Pioneering experiments performed by Harold Varmus
and Mike Bishop in 1976, led to one
of the most influential discoveries in
cancer research and identified the
first cancer-causing oncogene called Src.
Later experimental and clinical evidence suggested that Src kinase plays a
significant role in promoting tumor growth and progression and its activity is
assocated poor patient survival. Thus, several Src inhibitors were developed
and approved by FDA for treatment of cancer patients. Tumor microenvironment
(TME) is a highly complex and dynamic milieu where significant
cross-talk occurs between cancer
cells and TME-components, which consist of
tumor-associated macrophages, fibroblasts, and other immune and vascular cells.
Growth factors and chemokines activate multiple signaling cascades in TME and induce multiple kinases and
pathways, including Src, leading to tumor growth, invasion/metastasis, angiogenesis,
drug resistance and progression. Here, we will sytemically evaluate recent
findings regarding regulation of Src and significance of targeting Src in
cancer therapy